Archive | Atrial Fibrillation RSS feed for this section
bottle-of-pills-stock

Should Atrial Fibrillation Patients Take Oral Anticoagulants? (video)

A majority of atrial fibrillation patients who have not been treated oral anticoagulants (OAC) meet guideline indications for treatment. Untreated patients are at increased risk for adverse outcomes. In this video, AJM editor-in-chief Dr. Joseph S. Alpert discusses this new research in the April 2017 issue of the American Journal of Medicine. Read the Research: […]

Read more
electrocardiogram print out with stethoscope

Silent Atrial Fibrillation and Cryptogenic Strokes

A new suspected cause of cryptic strokes is “silent atrial fibrillation.” Pacemakers and other implanted devices allow continuous recording of cardiac rhythm for months or years. They have discovered that short periods of atrial fibrillation lasting minutes or hours are frequent and usually are asymptomatic. A meta-analysis of 50 studies involving more than 10,000 patients […]

Read more
The patient brought this smartphone photograph (submitted with her permission) to the clinic. It revealed well-demarcated anterior tongue discoloration that occurred with food intake. Her primary care provider thought that the changes were likely ischemic secondary to vasculitis and initiated treatment and a workup for giant cell arteritis.

A Picture’s Worth: Giant Cell Arteritis

The ubiquitous smartphone became a helpful diagnostic tool when a patient used one to snap a photograph of her tongue. Although her symptoms were vague and nonspecific, her photograph facilitated the diagnosis of a serious, potentially debilitating illness. A generally healthy 63-year-old woman presented with a 1-week history of sore throat and periodic burning tongue […]

Read more
Antithrombotic strategy by CHA2DS2-VASc score. DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TT = triple antithrombotic therapy (oral anticoagulation plus dual antiplatelet therapy).

Triple vs Dual Antithrombotic Therapy in Patients with AF & CAD

Background The role of triple antithrombotic therapy vs dual antithrombotic therapy in patients with both atrial fibrillation and coronary artery disease remains unclear. This study explores the differences in treatment practices and outcomes between triple antithrombotic therapy and dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Methods Using the Outcomes Registry […]

Read more
Quarterly visits for atrial fibrillation by anticoagulant type. DOAC = direct oral anticoagulant.

National Trends in Ambulatory Oral Anticoagulant Use

A nationally representative audit of outpatient office visits shows that direct oral anticoagulants, associated with increased use of oral anticoagulation for patients with atrial fibrillation, are being rapidly adopted. Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive […]

Read more
Antithrombotic drug prescription at inclusion and discharge when the following interventions were performed at the time of the survey or planned at discharge: pharmacologic cardioversion (A), electrical cardioversion (B), or catheter ablation (C). AP = antiplatelet; OAC = oral anticoagulation.

‘Real-World’ Antithrombotic Treatment in AF

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey   Background Current guidelines strongly recommend that oral anticoagulation should be offered to patients with atrial fibrillation and ≥1 stroke risk factors. The guidelines also recommend that oral anticoagulation still should be used in the presence of stroke risk factors irrespective of rate or rhythm […]

Read more
UA-42320404-1